A concise history of gout and hyperuricemia and their treatment by Nuki, George & Simkin, Peter A
Page 1 of 5
(page number not for citation purposes)
Available online http://arthritis-research.com/content/8/S1/S1
Abstract
First identified by the Egyptians in 2640 BC, podagra (acute gout
occurring in the first metatarsophalangeal joint) was later
recognized by Hippocrates in the fifth century BC, who referred to it
as ‘the unwalkable disease’. The term is derived from the Latin
word gutta (or ‘drop’), and referred to the prevailing medieval belief
that an excess of one of the four ‘humors’ – which in equilibrium
were thought to maintain health – would, under certain circum-
stances, ‘drop’ or flow into a joint, causing pain and inflammation.
Throughout history, gout has been associated with rich foods and
excessive alcohol consumption. Because it is clearly associated
with a lifestyle that, at least in the past, could only be afforded by
the affluent, gout has been referred to as the ‘disease of kings’.
Although there is evidence that colchicine, an alkaloid derived from
the autumn crocus (Colchicum autumnale), was used as a
powerful purgative in ancient Greece more than 2000 years ago,
its first use as a selective and specific treatment for gout is
attributed to the Byzantine Christian physician Alexander of Tralles
in the sixth century AD. Uricosuric agents were first used at the end
of the 19th century. In the modern era, nonsteroidal anti-
inflammatory drugs are usually the drugs of choice for treating
acute gout. Perhaps the most important historical advance in the
treatment of hyperuricemia was the development of xanthine
oxidase inhibitors, which are effective in reducing plasma and
urinary urate levels and have been shown to reverse the
development of tophaceous deposits.
Introduction
Gouty arthritis was among the earliest diseases to be
recognized as a clinical entity. First identified by the Egyptians
in 2640 BC [1], podagra (acute gout occurring in the first
metatarsophalangeal joint) was later recognized by
Hippocrates in the fifth century BC, who referred to it as ‘the
unwalkable disease’. Some of Hippocrates’ remarkable
clinical perceptions in relation to gout are preserved in
aphorisms, which are as true today as they were 2500 years
ago (Table 1) [2]. Hippocrates also noted the link between
the disease and an intemperate lifestyle, referring to podagra
as an ‘arthritis of the rich’, as opposed to rheumatism, an
arthritis of the poor. Six centuries later, Galen was the first to
describe tophi, the crystallized monosodium urate deposits
that can follow longstanding hyperuricemia. Galen associated
gout with debauchery and intemperance, but also recognized
a hereditary trait [3] that had previously been referred to by
the Roman senator Seneca [4].
The first person to use the word ‘gout’ to describe podagra
(gutta quam podagram vel artiticam vocant – ‘the gout that is
called podagra or arthritis’) was the Dominican monk
Randolphus of Bocking, domestic chaplain to the Bishop of
Chichester (1197–1258) [5]. The term is derived from the
Latin word gutta (or ‘drop’), and referred to the prevailing
medieval belief that an excess of one of the four ‘humors’ –
which in equilibrium were thought to maintain health – would,
under certain circumstances, ‘drop’ or flow into a joint,
causing pain and inflammation. Later, gout was described by
Thomas Sydenham, the famous English physician and
proponent of hippocratic medicine, who was himself disabled
by gout and renal disease [6]:
“The patient goes to bed and sleeps quietly until
about two in the morning when he is awakened by a
pain which usually seizes the great toe, but sometimes
the heel, the calf of the leg or the ankle. The pain
resembles that of a dislocated bone … and this is
immediately succeeded by a chillness, shivering and a
slight fever … the pain … , which is mild in the
beginning … , grows gradually more violent every hour
… so exquisitely painful as not to endure the weight of
the clothes nor the shaking of the room from a person
walking briskly therein.”
Throughout history gout has been associated with rich foods
and excessive alcohol consumption. Because it is clearly
associated with a lifestyle that, at least in the past, could only
be afforded by the affluent, gout has been referred to as the
‘disease of kings’. In some eras gout was perceived as socially
desirable because of its prevalence among the politically and
socially powerful. In his classic monograph on the history of
gout [5], Copeman refers to a comment in the London Times
in 1900, “The common cold is well named – but the gout
seems instantly to raise the patient’s social status”, and to
another in Punch in 1964, “In keeping with the spirit of more
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democratic times, gout is becoming less upper-class and is
now open to all … It is ridiculous that a man should be barred
from enjoying gout because he went to the wrong school.”
In earlier times, attacks of gout were also seen as a
prophylactic against more serious diseases. According to the
writer Horace Walpole [7], gout “prevents other illnesses and
prolongs life … could I cure that gout, should not I have a
fever, a palsy, or an apoplexy?”
In recent decades, however, the diet and lifestyle that
predispose individuals to hyperuricemia and gout have
become increasingly common. The role of excess dietary
purines (derived from meat, seafood, and beer) in the
development of gout is illustrated by the disparity between the
incidence of gout in Asia and Europe. Traditional Asian diets,
based on rice and vegetables, are low in dietary purines, and
gout has been relatively rare in these cultures. In contrast,
European and American diets, which are high in meat and
certain seafoods, are associated with hyperuricemia and gout
[8,9]. Increasing affluence has also led to an expansion in the
number of people following a westernized diet and lifestyle,
and this has been paralleled by an increase in the incidence
and prevalence of gout worldwide.
Historically, gout has been considered to be primarily a male
disease. The fact that women can also develop gout was first
recognized during the reign of Nero (AD 54–68) by Seneca,
who observed, “in this age, women rival men in every kind of
lasciviousness … why need we then be surprised at seeing
so many of the female sex afflicted with the gout?” [4]. In the
modern era, although gout remains primarily a disease of men
in middle age, it has become increasingly more frequent in
women, particularly after the menopause.
Uric acid as a factor in the causation of gout
Antoni van Leeuwenhoek (1632–1723), one of the pioneers of
microscopy, was the first to describe the appearance of the
crystals from a gouty tophus, although their chemical
composition was unknown at that time. He wrote in 1679 [10]:
“I observed the solid matter which to our eyes
resembles chalk, and saw to my great astonishment
that I was mistaken in my opinion, for it consisted of
nothing but long, transparent little particles, many
pointed at both ends and about 4 ‘axes’ of the
globules in length. I can not better describe that by
supposing that we saw with naked eye pieces from a
horse-tail cut to a length of one sixth of an inch.”
Fifty-five years later the physician and noted antiquarian
William Stukeley, who also suffered from gout, described the
crystals from a tophaceous joint [11]. In 1776 the chemical
identity of uric acid was first established as a constituent of a
renal calculus by the Swedish chemist Scheele [12], and the
English chemist Woolaston demonstrated urate in a tophus
from his own ear in 1797 [13]. Fifty years later, Sir Alfred
Baring Garrod described his famous ‘thread test’, a
semiquantitative method for the measurement of uric acid in
the serum or urine; it was the first clinical chemical test ever
undertaken [14]. In his remarkable volume The Nature and
Treatment of Gout and Rheumatic Gout (1859) [15], Garrod
stated that, “the deposited urate of soda may be looked upon
as the cause, and not the effect, of the gouty inflammation”.
Experimental support for this hypothesis later came from
Freudweiler’s demonstration that acute gouty arthritis could
be precipitated by the intra-articular injection of microcrystals
of sodium urate [16] and from the work of His [17], which
demonstrated the formation of tophi following subcutaneous
injection of urate crystals. These experiments were over-
looked for more than half a century until the publication of a
seminal paper by McCarty and Hollander [18], which showed
that crystals from the synovial fluid of patients with gout were
composed of monosodium urate. Their classic report
described the use of compensated polarized light microscopy
to examine joint fluid for crystals, and this technique was
subsequently used to identify calcium pyrophosphate
dehydrate crystals in synovial fluid from the joints of patients
with chondrocalcinosis and ‘pseudogout’ [19].
It was recognized that gout could be inherited as early as the
second century AD by the distinguished Cappadocian
physician Aretaeus, who described what he called a gouty
‘diathesis’ [20]. However, it was to be the 18th century
before gout became associated with certain external, and
possibly inherited, physical characteristics by the Edinburgh
physician William Cullen, who wrote, “The gout attacks men
of especially robust and large bodies, men of large heads …
and men whose skins are covered with a thick rete mucosum
with coarse surface … especially men of a choleric-sanguine
type … [whose fathers had suffered]” [5]. In 1771, William
Cadogan asked, “If the features of the countenance, the
outside of the body, are often hereditary, why not also the
inside?’ Despite these observations, it was not until 1931
that Sir Archibald Garrod (the son of Sir Alfred Garrod)
suggested that gout be included among disorders that could
result from ‘inborn errors of metabolism” [21], and the first
specific purine enzyme deficiency to be associated with a
rare type of inherited gout was not described until 1967 [22].
Table 1
Five aphorisms of Hippocrates on gout
Aphorism Details
VI-28 Eunuchs do not take the gout, nor become bald
VI-29 A woman does not take the gout, unless her menses be 
stopped
VI-30 A youth does not get gout before sexual intercourse
VI-40 In gouty affections, inflammation subsides within 40 days
XI-55 Gouty affections become active in spring and in autumn
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Earlier, Seegmiller and colleagues [23] had described the
relative roles of excessive urate production and impaired
excretion in the pathogenesis of hyperuricemia.
Treatments for gout through the ages
Although there is evidence that colchicine, an alkaloid derived
from the autumn crocus (Colchicum autumnale), was used as
a powerful purgative in ancient Greece more than 2000 years
ago [5], its first use as a selective and specific treatment for
gout is attributed to the Byzantine Christian physician
Alexander of Tralles in the sixth century AD [5]. Although
colchicine was useful for the treatment of acute gout, it was
recognized from earliest times that it could cause severe
gastrointestinal side effects. Because of the great influence
of Thomas Sydenham (‘the English Hippocrates’), who
rejected all medications that were purgatives as being too
toxic for use, colchicine was not used for the treatment of
gout for about 150 years [5] until its rediscovery in 1763 by
Professor Baron Von Stoerk in Vienna [24]. In the modern
era, nonsteroidal anti-inflammatory drugs (NSAIDs) are
usually the drugs of choice for treating acute gout, whereas
selective cyclo-oxygenase-2 inhibitors and intra-articular or
systemic corticosteroids are used less frequently to control
acute attacks in patients with relative contraindications to
NSAIDs [25].
Although diet has long been recognized as a major causative
factor in the pathogenesis of hyperuricemia and gout, dietary
restriction or modification as a means of controlling gout and
hyperuricemia has been and continues to be largely
neglected. AB Garrod was among the first to suggest that
hyperuricemia could be controlled by lowering the intake of
purine-rich food [26]. This was confirmed by Haig in a series
of clinical experiments he conducted on himself from 1894 to
1897 [27], and more recently in clinical physiological studies
on patients given purine-free formula diets [28].
Uricosuric agents, which enhance the renal clearance of
urate, were first used at the end of the 19th century [29]. See
(1877) [30] was able to induce uricosuria and resolution of
tophi in a patient with gout by administering large doses of
salicylates. However, salicylates have a bimodal effect on
urate excretion; at low doses they reduce urate excretion,
whereas at high doses (4–6 g/day) they are uricosuric [31].
Salicylates were, however, not long used for treating patients
with gout because of the toxicity and impracticality of high-
dose therapy, and they were supplanted as uricosuric agents
by probenecid [32], sulfinpyrazone [33], and benzbromarone
[34]. More recently, the antihypertensive agent losartan (an
angiotensin II antagonist) and the lipid-lowering fibrate
fenofibrate were shown to have moderate uricosuric effects
[35,36], although neither is licensed for the treatment of gout
or hyperuricemia.
In most mammalian species that express the enzyme urate
oxidase (uricase), which converts urate to the more soluble
and easily excreted compound allantoin, urate levels are low
and gout does not occur. In 1957, London and Hudson
published the first report of the use of uricase in two
individuals: one with a long history of typical gouty arthritis
and the other with no medical history of gout [37]. By
measuring urinary allantoin and serum uric acid levels, the
investigators determined that purified uricase, administered
intravenously, has potent uricolytic activity. Infusion of
recombinant fungal uricase has also been shown to be
effective in preventing acute uric acid nephropathy due to
tumor lysis in patients with malignancies [38]. However, the
short half-life and potential immunogenicity of fungal uricase
limits its prolonged use for treating chronic gout. Phase III
trials of a pegylated, recombinant porcine uricase for chronic
treatment of gout are currently underway.
Perhaps the most important historical advance in the
treatment of hyperuricemia was the development of
allopurinol, the first xanthine oxidase inhibitor [39]. George
Hitchings and Gertrude Elion were awarded the 1988 Nobel
prize in medicine for their work in developing allopurinol,
azathioprine, and five other drugs. Allopurinol has since
become the most frequently used uric acid lowering drug in
clinical practice. Xanthine oxidase inhibitors, which act by
inhibiting the synthesis of uric acid from hypoxanthine and
xanthine, are effective in reducing plasma and urinary urate
levels and have been shown to reverse the development of
tophaceous deposits. Oxypurinol, the active metabolite of
allopurinol, can be obtained for compassionate use in some
countries [40], and febuxostat, a novel selective inhibitor of
xanthine oxidase, has recently completely phase II [41] and
phase III [42] clinical trials, which have shown it to be highly
effective in lowering uric acid levels in patients with chronic
gout and hyperuricemia.
Asides on the influence of gout on American
political history
William Pitt: gout, taxes and the American colonies
The disabling gouty arthritis of the British statesman William
Pitt the Elder was a major factor in Britain’s loss of the
American colonies. It was during one of Pitt’s gout-related
absences from Parliament that the Stamp Act (1765) was
passed, which forced the unwilling colonists to pay a tax,
determined by the British Parliament, to defray the costs of
defending the colonies against French attack. Upon
recovering from his gout, Pitt succeeded in getting the Act
repealed with the famous words, “The Americans are the
sons, not the bastards, of England. As subjects, they are
entitled to the right of common representation and cannot be
bound to pay taxes without their consent.” Unfortunately,
during another of Pitt’s absences due to an episode of gout,
Lord Townshend persuaded Parliament to levy a heavy duty
on colonial imports of tea to raise the necessary revenues.
This precipitated the Boston Tea Party in 1773, and the rest
is history! (From Copeman [5].)
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pivotal figures during the American Revolution whose
relationships were crystallized by their gout affliction
Gout played a role in the outcome, as well as the origins, of
the American Revolution, the signing of the Declaration of
Independence, and the ratification of the Constitution.
Benjamin Franklin – the only person to have signed all three
founding documents of the USA – suffered from severe gout,
as did Thomas Jefferson and the Comte de Vergennes, a
French nobleman who was instrumental in obtaining the
money to finance the Revolution. Reportedly, Franklin was so
severely afflicted by gout that he was carried by convicts in a
sedan chair to the Constitutional Convention. Some have
speculated that these pivotal figures in American history had
such strong connections because they were all sufferers of
gout. (From Schwartz [1].)
John Hancock may have used gout for political leverage
By 9 January 1788, five of the nine required states had ratified
the Constitution. One notable holdout was Massachusetts,
whose governor, revolutionary leader John Hancock, was
unable to make up his mind on the Constitution and took to his
bed with what was seen at the time as a convenient case of
gout. Later, after being tempted by the Federalists with the
vice presidency, Hancock experienced a miraculous cure and
delivered his critical block of votes. On 6 February, with the
Federalists agreeing to recommend the addition of a bill of
rights, Massachusetts ratified the Constitution by a slim
margin. (From the National Archives [43].)
Conclusion
With a history spanning more than 2500 years, gout is
among the oldest recognized diseases. Its profound impact
on patient quality of life, as illustrated in memorable medical
cartoons and images (Figs 1 and 2), has even influenced
historical events (see Historical asides, above).
During the past 50 years advances in understanding the
causes and pathophysiology of hyperuricemia and gout, have
led to the development of effective therapies. As a result gout
has become a paradigm for the rational treatment and
prevention of a chronic rheumatic disease.
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